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In the course of radiation therapy diffe-
rent types of adverse reactions of the
skin are observed in approximately 95%
of patients. Among the various compli-
cations encountered after radiotherapy,
radiation recall dermatitis (RRD) dese-
rves special attention. Radiation der-
matitis is a form of delayed hypersen-
sitivity of irradiated skin, and the direct
trigger factors are medicines – most
chemotherapeutics. The reaction is an
inflammatory dermatosis. It is limited
to previously irradiated skin and appe-
ars a number of months after radiothe-
rapy. The aetiology of RRD is still uncle-
ar. Its clinical presentation may vary
from mild erythema to necrosis and
ulceration. The article presents the case
of a 50-year-old patient, who after
radiotherapy for breast cancer, during
the hormonal therapy (tamoxifen),
developed RRD type skin reactions after
skin application of Amol. The article pre-
sents a detailed differential diagnosis
of skin changes of RRD type, and
discusses the principles of treatment
and prevention.
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The advances seen in recent years in the treatment of oncological dise-
ases, with the introduction of new and refinement of previously used
methods, have resulted in a significant increase in survival, and thus led to
an increase of adverse effects of anticancer therapy.
Patients undergoing radiotherapy – despite the use of more modern and
safer methods of oncological treatment – are still exposed to post-radiation
adverse reactions within the irradiated skin or mucous membranes [1].
Irradiation has a high risk of early and late adverse reactions [2]. In the
course of radiotherapy in approximately 95% of patients various types of
adverse reactions are observed in the skin [3]. Among all the radiation-indu-
ced skin reactions it is estimated that approximately 10% are associated with
a hypersensitivity reaction to care products used [4].
The frequency and severity of radiation-induced skin changes depend on
many factors: location and schedule of radiotherapy, radiation dose, and indi-
vidual sensitivity of the skin [5]. Skin areas particularly predisposed to radia-
tion-induced reactions are the armpits, nipples and folds under the breasts [3].
Early reactions of an erythematous radiation-induced pemphigoid, who-
se severity depends on the dose of radiation, show up about 2 weeks after
irradiation. Chronic changes called a late reaction might occur at a variously
long time after irradiation, and their incidence is difficult to assess. Severe
adverse reactions are partly attributable to endothelial cell damage, and chro-
nic reactions combined with the proliferation of capillaries with increased
post-inflammatory fibrosis [2]. Among the various common late complica-
tions after irradiation, radiation recall dermatitis (RRD) deserves special atten-
tion. It is a severe inflammatory reaction limited to skin previously irradiated
by X-rays, and appears many months after radiotherapy.
Case report 
A patient aged 50 was admitted to the Department of Dermatology, Jagiel-
lonian University with well-bordered erythematous-infiltrative-oede matous
lesions located on the skin of the right arm and shoulder and the anterior
and posterior chest wall on the right side. In the interview, the appearance
of skin lesions was preceded by flu-like symptoms (musculoskeletal pain –
joint pain, fever to 39°C, weakness – 5 days before hospitalization). The patient
suspected flu and took medicine from the group NSAIDs (aspirin, ibuprofen)
and she used Amol fluid on her chest and arms. As a result of the procedu-
re used general symptoms showed significant remission, while on the skin
of the chest on the right side, as well as around the shoulder and arm, ery-
thema appeared, sharply demarcated from the healthy skin, and erythema-
tous-infiltrative, live-and-red colour, which was the cause of stopping treat-
ment and notification of the Department of Dermatology, UJCM (Fig. 1, 2).
On admission, body temperature was normal, and the patient did not report
any flu-like symptoms. During the dermatological examination there was
persistent induration around the inflamed skin, slightly painful on pressure
and slight features of lymphoedema of the right upper limb.
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The physical examination revealed healed scars: under
the right armpit linear, vertical, length about 10 cm (in the
anterior axillary line) and oblique, length approx 7 cm, on
the border of the upper and lower outer quadrant of the
right breast, resulting from the surgical removal of carci-
noma with pathological weaving ductale infiltrans et mul-
tifocal intraductal – cribriforme – mammae along with exci-
sion of regional lymph nodes in the right armpit. The
procedure was performed in November 2008. In the exa-
mined lymph node metastasis was found (1/15). Initially 
3-month chemotherapy was administered (doxorubicin and
cyclophosphamide) followed by radiotherapy (April-June
2009). Treatment with tamoxifen was continued for ano-
ther 4 months until the appearance of the symptoms.
During hospitalization at the Department of Dermatology,
UJCM, in the laboratory parameters there were observed:
increased inflammation (Biernacki’s reaction – 54/94 mm/h,
CRP – 20.9 mg/l) without accompanying leukocytosis, mar-
ked levels of ASO did not exceed 200 IU/ml. In addition to
abnormal liver function tests (ALT: 70 U/l, AST: 29 U/l, GGT:
130 U/l), other parameters including the results of imaging
tests (chest radiograph, abdominal ultrasound) were nor-
mal. Excluded deviations above the background virus. The
patient did not consent to biopsy of the infiltrated area. An
indirect way of exclusion of neoplastic infiltration was to
determine the nature of the tumour marker Ca 15-3 (the
result of: 13.15 U/ml [N < 25]).
Due to the significantly elevated inflammatory parame-
ters, clinical changes suggestive of the diagnosis and inte-
rview erysipelas on the arm, intravenous antibiotic linco-
mycin was begun (at a dose of 3 × 600 mg i.v. for 3 days,
then 2 × 600 mg i.v. for 2 consecutive days), but it did not
yield dermatological improvement. After consultation with
the oncologist tamoxifen therapy was discontinued. Recent
treatment was modified and intramuscular injections of
dexamethasone were administered (initial dose of 16-4 mg)
and antihistamines (cetirizine after), anticoagulants (low
molecular weight heparin s.c.) and vascular (diosmin). Clo-
betasol ointment was applied externally.
After three days of treatment a significant improvement
was achieved – 90% of skin lesions resolved, reducing pain
and improving the patient’s general condition. The patient
was discharged home on the 7th day of hospitalization in 
a very good condition (Fig. 3, 4). Complete remission of skin
lesions occurred after 4 weeks. The patient remained under
observation by our outpatient clinic until complete resolu-
tion of skin lesions.
Although the first descriptions of RRD appeared in the
literature in the 1960s, both the magnitude of the pheno-
menon, and especially the mechanisms of its formation
remain unknown [5]. The exact mechanism of RRD is not
known, but several hypotheses that may explain the deve-
lopment of late radiation-induced skin changes have been
proposed. These mechanisms include changes in the blood
supply in post-irradiative skin with increased vascular per-
meability, combined with excessive expression of TGF-β and
proinflammatory cytokines [6]. Other authors have empha-
sized the role of abnormalities of DNA repair mechanisms,
as well as increased sensitivity to drugs [7, 8]. The develop-
ment of RRD is also explained as a result of post-radiation
reduction of the number and impaired function of epithelial
stem cells of the epidermis with increased susceptibility to
Fig. 1. Sharply demarcated erythematous and infiltrated skin
lesions localized on the chest and right shoulder 
Fig. 2. Irregular erythematous skin changes on the hard surface
of inflammatory infiltration, placed on the arm and on the right
side of back 
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external factors [6]. Some compare the pathogenesis of this
reaction to the Koebner phenomenon [9].
Currently, it is assumed that RRD is a form of delayed
sensitivity of skin previously irradiated by X-ray, and that
a direct causative factor is drugs – most chemotherapeutic
agents [10].
Radiation recall dermatitis type reaction is defined as
a rare inflammatory dermatosis, which is elicited within the
irradiated skin [11]. The aetiology and incidence are not yet
clarified [12]. Kodym et al., based on observations in 142
patients who underwent prior radiation treatment for can-
cer, evaluated the incidence of RRD-type reaction at 8.8%
[13]. Most of the literature suggests that chemotherapeu-
tic agents are responsible for the development of RRD-type
reaction in previously irradiated skin [1, 6, 7, 14-17]. It is esti-
mated that one of the essential elements for the risk of
developing RRD-type reaction is the time from the moment
of the completion of radiotherapy until the incorporation of
chemotherapy. The is less than the risk of developing a gre-
ater response [7, 18]. It was noted that the time between
the start of treatment with provocative and the appearan-
ce of the lesions may take from several days to several
weeks or months [11, 19]. It is understood that the predi-
sposition to late post-irradiative dermatitis is dependent on
immuno-vascular changes within the irradiated skin, which
predisposes to the revised distribution of drugs – mainly
cytostatic drugs (e.g. tamoxifen) in tissue treated with pre-
radiotherapy [6, 7]. The consequence may be substantial,
fixed previously irradiated skin sensitivity to external fac-
tors, such as creams or UV radiation [4, 10].
The clinical picture of changes of RRD type is characte-
rized by great diversity: from light red by changing the ery-
thematous-maculo-papular-oedematous to severe skin
necrosis. However, the changes are always limited to pre-
viously irradiated skin [11]. In the treatment of late postra-
diative dermatitis, in addition to required interruption of
therapy with the suspected drug, local and systemic stero-
ids and antihistamines are used [1]. For the prevention of
recurrence of skin lesions associated with RRD, the chronic
use of local steroids is proposed [20]. Bauer et al. describe
a case of complete resolution of skin lesions, without inter-
ruption of chemotherapy after local treatment with hyalu-
ronic acid [21].
Bespoke design and unspecific clinical signs of disease
described by our patient resulted in different differential
diagnoses being considered, both dermatological and non-
dermatological causes.
Flu-like symptoms, clearly demarcated from the surro-
unding skin erythematous-oedematous changes with
a smooth surface tensions well initially suggested the dia-
gnosis of erysipelas, which was eventually ruled out (despi-
te the lack of improvement following intravenous antibio-
tics and a low level of ASO, leukocytosis, a slight increase
of C-reactive protein and ESR). Because of the tumour inte-
rview included in the differential diagnosis of breast cancer
metastasis to the skin (so-called erysipelas carcinomato-
sum). These diagnoses were excluded on the basis of the
indirect marker of normal values of Ca 15-3 and oncologi-
cal outcome of the consultation (the patient did not con-
sent to biopsy) [22, 23]. In the differential diagnosis the
possibility of allergic contact dermatitis or irritation was
taken into account [3]. Appearance of the skin lesions was
preceded by application to all skin of Amol – a herbal pre-
paration based on alcohol – which was applied because of
the patient’s flu-like symptoms.
Finally, in the whole clinical picture of the results of labo-
ratory tests and observing a significant improvement after
treatment with local steroid and antiallergic drugs, RRD
during tamoxifen therapy was diagnosed [6]. It seems that
in the case described, Amol use may be the factor that ini-
tiated the development of the RRD-type reaction within the
previously irradiated skin.
Fig. 3. Front of the chest after general steroidotherapy Fig. 4. Discrete postinflammatory changes after 7 days of stero-
idotherapy 
170 współczesna onkologia/contemporary oncology 
References 
1. Putnik K, Stadler P, Schäfer C, Koelbl O. Enhanced radiation sensiti-
vity and radiation recall dermatitis (RRD) after hypercin therapy –
case report and review of literature. Radiation Oncology 2006; 1: 32. 
2. James WD, Odom RB. Late subcutaneous fibrosis following mega-
voltage radiotherapy. J Am Acad Dermatol 1980; 3: 616-8. 
3. Porock D. Skin reactions during radiotherapy for breast cancer; the
use and impact of topical agents and dressing. European journal
of cancer care 1999; 8: 143-53. 
4. Leverkus M, Schwaaf A, Bröcker EB, Rünger TM. Recurrent hemoly-
sis-associated pseudoerysipelas of the lower legs in a patient with
congenital spherocytosis. J Am Acad Dermatol 2004; 51: 1019-23. 
5. Turesson I. Individual variation and dose deoendency in the pro-
gession rate of skin telangiectasia. Int j radiatoncol boil Phys 1990;
19: 1569-74. 
6. Kundranda MN, Daw HA. Tamoxifen-induced radiation recall der-
matitis. J Am of ClinOncol 2006; 29: 637-38. 
7. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall:
another call with tamoxifen. Acta Oncologica 1999; 38: 955-9. 
8. Camidge R, Price A. Characterizing the phenomenon of radiation
recall dermatitis. Radiother Oncol 2001; 59: 237-45. 
9. Camidge R, Price A. Radiation recall dermatitis may represent the
Koebner phenomenon. J Clin Oncol 2002; 2: 4130. 
10. Ledet JJ, Grafton LH. Tamoxifen-induced ultraviolet, recall dermati-
tis. J Drugs Dermatol 2009; 8: 761-2. 
11. Guarneri C, Guarneri B. Radiation recall dermatitis. CMAJ 2010; 182:
E150. 
12. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer thera-
py. Curr Opin Oncol 2002; 14: 212-6. 
13. Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R,
Hohenberg G. Frequency of radiation recall dermatitis in adult can-
cer patients. Onkologie 2005; 28: 18-21. 
14. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recogni-
zed but neglected phenomenon. Cancer Treat Rev 2005; 31: 555-7. 
15. Ash RB, Videtic GM. Radiation recall dermatitis after the use of ano-
rexiant phentermine in a patient with breast cancer. Breast J 2006;
12: 186-7. 
16. Kaya TI, Tiftik N, Tursen U, Ikizoglu G, Yalcin A. Ultraviolet recall phe-
nomenon associated with methotrexate and cytarabine. J Eur Acad
Dermatol Venereol 2006; 20: 353-4. 
17. Mizumoto M, Harada H, Asakura H, Zenda S, Fuji H, Murayama S,
Nishimura T. Frequency and characteristics of docetaxel-induced
radiation recall phenomenon. Int J Radiat Oncol Biol Phys 2006; 66:
1187-91. 
18. Del Giudice SM, Gerstley JK. Sunlight – induced radiation recall. Int
Dermatol 1988; 27: 415-6. 
19. Bronner AK, Hood AF. Cutaneous complications of chemiothera-
peutic agent. J Am Acad Dermatol 1983; 9: 654-63. 
20. Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation
recall dermatitis: case report and review of the literature. Curr Oncol
2008; 15: 53-62. 
21. Bauer SM, Bauer C. The use of sodium hyaluronate for the treat-
ment of radiation recall dermatitis. J Oncol Pharm Pract 2009; 15:
123-6. 
22. Lo/ kkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G. Skin tre-
atment with Bepanthen cream versus no cream during radiothe-
rapy Acta Oncologica 1996; 35: 1021-26. 
23. Petit A, Sigal M, Merat R, Pepin E, Couffinhal JC. Pseudoerysipelas
resulting from acute anterior tibial compartment syndrome. J Am
Acad Dermatol 1996; 34: 521-2. 
Address for correspondence
Aleksander Obtułowicz MD 
Department of Dermatology 
Jagiellonian University Medical College 
Skawińska 8   
31-066 Krakow, Poland
e-mail: obtulowicz@poczta.fm
171Radiation recall dermatitis induced by Amol during tamoxifen therapy – case report
